What is Arsuamoon used for?

Arsuamoon is indicated for Falciparum malaria, Vivax malaria.

Arsuamoon is developed by Pfizer.

What development phase is Arsuamoon in?

Arsuamoon is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Arsuamoon

Pfizer · FDA-approved active Small molecule Quality 7/100

Arsuamoon, marketed by Pfizer, is a treatment for falciparum malaria. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity. The primary risk is the potential increase in competition following patent expiration.

At a glance

Generic name	Arsuamoon
Sponsor	Pfizer
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	FDA-approved

Approved indications

Falciparum malaria
Vivax malaria

Common side effects

No common side effects on file.

Key clinical trials

Bioequivalence Study Comparing Artesunate Tablet To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects (PHASE1)
A Study Comparing Blood Levels After Single-Dose Administration Of Artesunate Sachets (Pfizer) Versus Single-Dose Administration Of Arsuamoon® Tablets (Guilin-China) In Healthy Subjects (PHASE4)
A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Arsuamoon CI brief — competitive landscape report
Arsuamoon updates RSS · CI watch RSS
Pfizer portfolio CI